CHICAGO — The American Medical Association (AMA), the nation’s largest medical association, announces the re-election of Buffalo, New York-based urologist Willie Underwood III, M.D., M.P.H., to its board of directors bottom. Dr. Underwood will also serve as chairman from 2023-2024.
“Professionalism, advocacy and ethics, the goals for which the AMA was founded over 175 years ago, are as noble and valuable today as they were then, and I am proud to be a part of such a proud tradition. I am honored,” said Dr. under the tree. “As we rebuild and recover from the COVID-19 pandemic, I look forward to working with my colleagues in the medical community to advance the AMA Recovery Plan for American physicians. Amending preapproval, reforming Medicare payments, and reducing physician burnout are crucial steps at this critical time for health care and healthcare.”
Dr. Underwood has been an active leader in organizational medicine for decades and was first elected to the AMA’s Board of Directors in 2019. He has chaired the AMA Legislative Council and the AMA Resident and Fellow Section and has also served as President of Erie County. He is a member of the New York Medical Association and he is an AMA representative of the American Urological Association (AUA).
Dr. Underwood is also a board-certified urologist with more than 20 years of experience in general urological surgery, including more than 10 years of experience specializing in robotic urological surgery, addressing medical disparities and I am an expert in health policy. He has served on several national and regional health policy committees, including a board member of the New York State Highmark Blue Cross Blue Shield and a member of the Joint Committee.
He has also served on the Board of Trustees and Medical Advisor of Love Canal Medical Fund Inc., on the AMA and the American Medical Association Commission to Eliminate Medical Disparities, and on the Urology Graduate Medical Education Accreditation Council. Residential Review Board.
In addition to co-authoring over 120 peer-reviewed publications, book chapters, and published abstracts, he has received millions of dollars in research funding from the National Institutes of Health and a patent for joint development of biomarkers for prostate cancer. Acquired in the United States and Japan. . He is the co-founder of his KAPS Biotechnology LLC, currently conducting large-scale validation studies of novel prostate cancer biomarkers.
Dr. Underwood received his M.D. and M.S. degrees. He earned his PhD from SUNY He Upstate Medical College and his MPH from the University of Michigan.
